Gomez-Bravo, MiguelPrieto Castillo, MartinNavasa, MiquelSanchez-Antolin, GloriaLlado, LauraOtero, AlejandraSerrano, TrinidadJimenez Romero, CarlosGarcia Gonzalez, MiguelValdivieso, AndresGonzalez-Dieguez, Maria Luisade la Mata, ManuelPons, Jose ASalcedo, MagdalenaRodrigo, Juan MCuervas-Mons, ValentinGonzalez Rodriguez, AntonioCaralt, MireiaPardo, FernandoVaro Perez, EvaristoCrespo, GonzaloRubin, AngelGuilera, MagdaAldea, AnnaSantoyo, Julio2023-05-032023-05-032022-04-05Gómez-Bravo M, Prieto Castillo M, Navasa M, Sánchez-Antolín G, Lladó L, Otero A, et al. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. Rev Esp Enferm Dig. 2022 Jun;114(6):335-3421130-0108http://hdl.handle.net/10668/21725Reduction in calcineurin inhibitor levels is considered crucial to decrease the incidence of kidney dysfunction in liver transplant (LT) recipients. The aim of this study was to evaluate the safety and impact of everolimus plus reduced tacrolimus (EVR + rTAC) vs. mycophenolate mofetil plus tacrolimus (MMF + TAC) on kidney function in LT recipients from Spain. the REDUCE study was a 52-week, multicenter, randomized, controlled, open-label, phase 3b study in de novo LT recipients. Eligible patients were randomized (1:1) 28 days post-transplantation to receive EVR + rTAC (TAC levels ≤ 5 ng/mL) or to continue with MMF + TAC (TAC levels = 6-10 ng/mL). Mean estimated glomerular filtration rate (eGFR), clinical benefit in renal function, and safety were evaluated. in the EVR + rTAC group (n = 105), eGFR increased from randomization to week 52 (82.2 [28.5] mL/min/1.73 m2 to 86.1 [27.9] mL/min/1.73 m2) whereas it decreased in the MMF + TAC (n = 106) group (88.4 [34.3] mL/min/1.73 m2 to 83.2 [25.2] mL/min/1.73 m2), with significant (p  EVR + rTAC allows a safe reduction in tacrolimus exposure in de novo liver transplant recipients, with a significant improvement in eGFR but without significant differences in renal clinical benefit 1 year after liver transplantation.enEverolimusDe novo liver transplantRenal functioneGFRKDIGODrug therapy, combinationEverolimusGraft rejectionGraft survivalHumansImmunosuppressive agentsKidneyLiver transplantationMycophenolic acidProspective studiesTacrolimusresearch article35469409open accessInmunosupresoresQuimioterapia combinadaRechazo de injertoRiñónSupervivencia de injertoTrasplante de hígadoÁcido micofenólico10.17235/reed.2022.8549/2021https://doi.org/10.17235/reed.2022.8549/2021